Nothing Special   »   [go: up one dir, main page]

IN2014CN02959A - - Google Patents

Info

Publication number
IN2014CN02959A
IN2014CN02959A IN2959CHN2014A IN2014CN02959A IN 2014CN02959 A IN2014CN02959 A IN 2014CN02959A IN 2959CHN2014 A IN2959CHN2014 A IN 2959CHN2014A IN 2014CN02959 A IN2014CN02959 A IN 2014CN02959A
Authority
IN
India
Prior art keywords
compounds
formula
abvdisclosed
het
salts
Prior art date
Application number
Other languages
English (en)
Inventor
Mark E Layton
Joseph E Pero
Hannah Fiji
Michael J Kelly Iii
Leon Pablo De
Michael A Rossi
Kevin F Gilbert
Anthony J Roecker
Zhijian Zhao
Swati Pal Mercer
Scott Wolkenberg
James Mulhearn
Lianyun Zhao
Dansu Li
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of IN2014CN02959A publication Critical patent/IN2014CN02959A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D451/00Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • C07D491/107Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
IN2959CHN2014 2011-10-28 2012-10-26 IN2014CN02959A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161552885P 2011-10-28 2011-10-28
PCT/US2012/062207 WO2013063459A1 (en) 2011-10-28 2012-10-26 Benzoxazolinone compounds with selective activity in voltage-gated sodium channels

Publications (1)

Publication Number Publication Date
IN2014CN02959A true IN2014CN02959A (ja) 2015-07-03

Family

ID=48168585

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2959CHN2014 IN2014CN02959A (ja) 2011-10-28 2012-10-26

Country Status (12)

Country Link
US (1) US9273040B2 (ja)
EP (1) EP2770995B1 (ja)
JP (1) JP2014532660A (ja)
KR (1) KR20140095067A (ja)
CN (1) CN103889419A (ja)
AU (1) AU2012328561A1 (ja)
BR (1) BR112014010197A2 (ja)
CA (1) CA2852796A1 (ja)
IN (1) IN2014CN02959A (ja)
MX (1) MX2014005068A (ja)
RU (1) RU2014121489A (ja)
WO (1) WO2013063459A1 (ja)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2855019A1 (en) 2011-10-31 2013-05-10 Xenon Pharmaceuticals Inc. Biaryl ether sulfonamides and their use as therapeutic agents
CN104024251B (zh) 2011-10-31 2017-08-11 克赛农制药股份有限公司 苯磺酰胺化合物及其作为治疗剂的用途
TW201400446A (zh) 2012-05-22 2014-01-01 Genentech Inc N-取代之苯甲醯胺及其使用方法
RU2015103913A (ru) 2012-07-06 2016-08-27 Дженентек, Инк. N-замещенные бензамиды и способы их применение
CN105263490B (zh) 2013-03-14 2018-05-22 基因泰克公司 取代的三唑并吡啶及其使用方法
EP2970156B1 (en) 2013-03-15 2018-07-25 Genentech, Inc. Substituted benzoxazoles and methods of use thereof
MX2016006936A (es) 2013-11-27 2016-10-05 Genentech Inc Benzamidas sustituidas y metodos para usarlas.
TW201623264A (zh) 2014-03-29 2016-07-01 魯賓有限公司 作為電位閘控鈉通道調節劑之磺胺化合物
JP2017525677A (ja) 2014-07-07 2017-09-07 ジェネンテック, インコーポレイテッド 治療用化合物及びその使用方法
AR103833A1 (es) * 2015-03-02 2017-06-07 Amgen Inc Compuestos bicíclicos de sulfonamida cetona
MA42118A (fr) 2015-05-22 2018-03-28 Genentech Inc Benzamides substitués et leurs méthodes d'utilisation
CN108137477A (zh) 2015-08-27 2018-06-08 基因泰克公司 治疗化合物及其使用方法
WO2017058821A1 (en) 2015-09-28 2017-04-06 Genentech, Inc. Therapeutic compounds and methods of use thereof
US10899732B2 (en) 2015-11-25 2021-01-26 Genentech, Inc. Substituted benzamides useful as sodium channel blockers
CN108699015A (zh) 2015-12-18 2018-10-23 默沙东公司 对电压门控性钠通道具有选择性活性的羟基烷基胺-和羟基环烷基胺-取代的二胺-芳基磺胺化合物
EP3436432B1 (en) 2016-03-30 2021-01-27 Genentech, Inc. Substituted benzamides and methods of use thereof
CN109526219B (zh) 2016-05-20 2021-03-12 泽农医药公司 苯磺酰胺及其作为治疗剂的用途
WO2018072602A1 (en) 2016-10-17 2018-04-26 Genentech, Inc. Therapeutic compounds and methods of use thereof
MA48583A (fr) 2016-12-09 2021-04-21 Xenon Pharmaceuticals Inc Composés de benzènesulfonamide et leur utilisation en tant qu'agents thérapeutiques
CN110546148A (zh) 2017-03-24 2019-12-06 基因泰克公司 作为钠通道抑制剂的4-哌啶-n-(嘧啶-4-基)色满-7-磺酰胺衍生物
WO2018205948A1 (en) * 2017-05-11 2018-11-15 Glaxosmithkline Intellectual Property Development Limited Compounds
AR114263A1 (es) 2018-02-26 2020-08-12 Genentech Inc Compuestos terapéuticos y métodos para utilizarlos
WO2019191702A1 (en) 2018-03-30 2019-10-03 F. Hoffmann-La Roche Ag Substituted hydro-pyrido-azines as sodium channel inhibitors
US11512072B2 (en) 2018-04-19 2022-11-29 University Of Virginia Patent Foundation Compositions and methods for preparing and using azetidines
AU2019285184B2 (en) 2018-06-13 2023-11-16 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
WO2020047312A1 (en) 2018-08-31 2020-03-05 Xenon Pharmaceuticals Inc. Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors
EA202190395A1 (ru) 2018-08-31 2021-06-15 Ксенон Фармасьютикалз Инк. Замещенные гетероарилом сульфонамидные соединения и их применение в качестве терапевтических средств

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09124620A (ja) 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
NZ511334A (en) 1998-12-04 2003-06-30 Neurosearch As Benzimidazolone derivatives useful as ion channel modulating agents
DK1598338T5 (da) 2001-04-18 2010-01-18 Euro Celtique Sa 1-(4-piperidinyl)-1,3-dihydro-2H-indol-2-on-derivater og relaterede forbindelser som nociceptinanaloger og ORL1-ligander til behandlingen af smerte
EP1467986A1 (en) 2002-01-17 2004-10-20 Eli Lilly And Company Aza-cyclic compounds as modulators of acetylcholine receptors
ZA200709961B (en) * 2005-05-10 2009-07-29 Vertex Pharma Bicyclic derivatives as modulators of ion channels
EP1888547A1 (en) * 2005-06-09 2008-02-20 Vertex Pharmaceuticals, Inc. Indane derivatives as modulators of ion channels
EP2316829A1 (en) 2005-12-21 2011-05-04 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives as modulators of ion channels
US8124610B2 (en) * 2007-07-13 2012-02-28 Icagen Inc. Sodium channel inhibitors
US20100048629A1 (en) 2008-08-21 2010-02-25 Allyson Gage Methods for treating neuropathic pain
PE20120008A1 (es) 2009-01-12 2012-01-24 Icagen Inc Derivados de fenoxi bencenosulfonamida
WO2010129596A1 (en) * 2009-05-04 2010-11-11 Agios Pharmaceuticals, Inc. Pmk2 modulators for use in the treatment of cancer

Also Published As

Publication number Publication date
WO2013063459A1 (en) 2013-05-02
RU2014121489A (ru) 2015-12-10
EP2770995B1 (en) 2019-01-02
AU2012328561A1 (en) 2014-04-17
CA2852796A1 (en) 2013-05-02
BR112014010197A2 (pt) 2017-04-18
AU2012328561A8 (en) 2014-05-01
JP2014532660A (ja) 2014-12-08
MX2014005068A (es) 2014-07-30
KR20140095067A (ko) 2014-07-31
CN103889419A (zh) 2014-06-25
EP2770995A1 (en) 2014-09-03
EP2770995A4 (en) 2015-06-03
US20140303143A1 (en) 2014-10-09
US9273040B2 (en) 2016-03-01

Similar Documents

Publication Publication Date Title
IN2014CN02959A (ja)
PH12019501321B1 (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3k-delta related disorders
PH12018501288A1 (en) Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels
SA515360229B1 (ar) مثبطات‎ ‎عامل التمايز والنمو 8‏
SA515360469B1 (ar) مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها
PH12015502615B1 (en) Chemical compounds
WO2014120808A8 (en) Pyridone amides as modulators of sodium channels
BR112015009216A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de uma composição farmacêutica
CL2015001599A1 (es) Compuestos derivados de (piridin o pirimidin)-(piperidina o piperazina) sustituidos o sus sales, inhibidores de la colesterol 24-hidroxilasa (ch24h); medicamento; metodo de inhibicion de la ch24h; metodo para prevenir o tratar; y uso para la prevencion o tratamiento de epilepsia, alzheimer y parkinson, entre otras enfermedades.
MX2015008957A (es) Fluoro-[1,3]oxazinas como inhibidores de beta-secretasa 1 (bace1).
HUE036040T2 (hu) Adaptor-asszociált kináz 1 gátlása fájdalom kezelésére
PH12015502365A1 (en) Bace1 inhibitors
MX2012001134A (es) Composiciones y metodos para inhibicion de la via jak.
PH12014502541A1 (en) 5-amino [1,4] thiazines as bace 1 inhibitors
WO2013040227A3 (en) Therapeutic compounds
NZ738672A (en) Therapeutic compounds and compositions for treating social disorders and substance use disorders
WO2014043252A3 (en) Hydroxypyridinone-,hydroxypyrimidinone-and hydroxypyridazinone drivatives and their therapeutic application
TN2015000275A1 (fr) 4-hydroxy-2-methyl-5-(propan-2-ylidene)cyclohex-3-enecarbaldehyde for the prevention and treatment of a cognitive, neurodegenerative or neuronal disease
IN2012DN06061A (ja)
WO2013148638A3 (en) Compositions and methods related to inhibitors of jak kinase
TN2013000150A1 (en) Co-crystals and salts of ccr3-inhibitors
WO2013121334A3 (en) Agents for treating neurodegenerative disorders
WO2013175347A3 (en) Compositions and methods for treatment of respiratory disorders